Advertisement
Advertisement
U.S. Markets close in 3 hrs 8 mins
Advertisement
Advertisement
Advertisement
Advertisement

Genetic Technologies Limited (GENE)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.82000.0000 (0.00%)
As of 12:52PM EST. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.8200
Open1.6800
Bid1.8400 x 1400
Ask1.8500 x 800
Day's Range1.6500 - 1.8700
52 Week Range0.8300 - 2.4000
Volume4,461,406
Avg. Volume1,681,309
Market Cap38.667M
Beta (5Y Monthly)1.22
PE Ratio (TTM)N/A
EPS (TTM)-0.6000
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Genetic Technologies to Launch Ground-breaking Comprehensive Risk Test for Breast & Ovarian Cancer

    MELBOURNE, Australia, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, is delighted to provide further update. The innovation and development of this test is inspired by direct response and feedback from the payer conversations such as insurance providers, employers, and healthcare providers. There is an unmet need to develop a unique single saliva risk asses

  • GlobeNewswire

    Genetic Technologies Announces $5 Million Registered Direct Offering

    MELBOURNE, Australia, Feb. 03, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE, “Company”, “GTG”, or “Genetic Technologies”), a global leader in guideline-driven genomics-based tests in health, wellness and serious diseases, today announced that it has entered into definitive agreements with several institutional investors for the purchase and sale in a registered direct offering of 3,846,155 American Depositary Shares (“ADSs”) (or ADS equivalent in lieu thereof), eac

  • GlobeNewswire

    GENE to Launch World’s First Comprehensive Risk Test for Breast & Ovarian Cancer

    MELBOURNE, Australia, Feb. 03, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”) a global leader in genomics-based tests in health, wellness and serious disease, is pleased to announce the Company will launch a ‘World First’ Comprehensive Risk Assessment Test which evaluates a women’s risk of developing Breast and/or Ovarian Cancer either from a hereditary genetic mutation or from the far more common familial or sporadic cancer. Combined with other

Advertisement
Advertisement